Current issue
Archive
Manuscripts accepted
About the Journal
Instructions for authors
Manuscripts accepted
Views: 42
Get citation
NUTRITION / STATE OF THE ART PAPER
Figure from article: Gut microbiota and arterial...
Download slide
Gut microbiota and arterial hypertension: a narrative review
Marcin Adamczak 1
,
 
Stanisław Surma 2
 
 
 
More details
Hide details
1
Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
 
2
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
 
 
Submission date: 2025-02-28
 
 
Final revision date: 2025-06-23
 
 
Acceptance date: 2025-07-08
 
 
Online publication date: 2025-08-23
 
 
Corresponding author
Marcin Adamczak   

Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia Francuska 20-24 40-027 Katowice, Poland Phone: +48 (32) 259-14-01
 
 
DOI: https://doi.org/10.5114/aoms/208012
 
 
Article (PDF)
References (85)
 
KEYWORDS
gut microbiota
dysbiosis
arterial hypertension
probiotics
prebiotics
synbiotics
 
TOPICS
ABSTRACT
In patients with hypertension, intestinal dysbiosis and increased intestine permeability are commonly observed. Modifications of intestinal microbiota with certain probiotics, prebiotics, and synbiotics, as well as gut microbiota transfer, have been associated with a reduction in blood pressure. Therefore, these interventions, especially probiotics, can be employed as adjuncts to hypertension therapy. Bacteria constituting dysbiotic intestinal microbiota produce compounds with hypertensinogenic activity (trimethylamine – TMA, pathogen-associated molecular patterns – PAMPs). In addition, in a state of dysbiosis, a decrease in the production of compounds with antihypertensive activity (short-chain fatty acids – SCFAs) is observed. A diet high in salt significantly alters the intestinal microbiota, and such dysbiosis has been implicated in the pathogenesis of salt-sensitive hypertension. This narrative review article discusses the importance of the gut microbiota, its dysbiosis in patients with hypertension, and potential therapeutic options.
REFERENCES (85)
1.
Wu X, Sha J, Yin Q, Gu Y, He X. Global burden of hypertensive heart disease and attributable risk factors, 1990-2021: insights from the global burden of disease study 2021. Sci Rep 2025; 15: 14594.
Google Scholar
 
 
2.
Lin L, Xiang S, Chen Y, et al. Gut microbiota: implications in pathogenesis and therapy to cardiovascular disease (Review). Exp Ther Med 2024; 28: 427.
Google Scholar
 
 
3.
Bielecka-Dabrowa A, Banach M, Wittczak A, et al. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper. Arch Med Sci 2023; 19: 841-64.
Google Scholar
 
 
4.
Cicero AFG, Fogacci F, Tocci G, et al. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus® and placebo. Arch Med Sci 2023; 19: 1169-79.
Google Scholar
 
 
5.
Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy. MedComm 2020 2025; 6: e70168.
Google Scholar
 
 
6.
Bhatia A, Sharma D, Mehta J, et al. Probiotics and synbiotics: applications, benefits, and mechanisms for the improvement of human and ecological health. J Multidiscip Healthc 2025; 18: 1493-510.
Google Scholar
 
 
7.
Dekaboruah E, Suryavanshi MV, Chettri D, Verma AK. Human microbiome: an academic update on human body site specific surveillance and its possible role. Arch Microbiol 2020; 202: 2147-67.
Google Scholar
 
 
8.
Ruan W, Engevik MA, Spinler JK, Versalovic J. Healthy human gastrointestinal microbiome: composition and function after a decade of exploration. Dig Dis Sci 2020; 65: 695-705.
Google Scholar
 
 
9.
Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016; 14: e1002533.
Google Scholar
 
 
10.
Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell 2010; 1: 718-25.
Google Scholar
 
 
11.
Rackaityte E, Lynch SV. The human microbiome in the 21st century. Nat Commun 2020; 11: 5256.
Google Scholar
 
 
12.
Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019; 7: 14.
Google Scholar
 
 
13.
Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: breaking down xenobiotic-microbiome interactions. Pharmacol Rev 2019; 71: 198-224.
Google Scholar
 
 
14.
Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80.
Google Scholar
 
 
15.
Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-8.
Google Scholar
 
 
16.
Riccio P, Rossano R. The human gut microbiota is neither an organ nor a commensal. FEBS Lett 2020; 594: 3262-71.
Google Scholar
 
 
17.
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015; 21: 8787-803.
Google Scholar
 
 
18.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis 2016; 22: 1137-50.
Google Scholar
 
 
19.
Upadrasta A, Madempudi RS. Probiotics and blood pressure: current insights. Integr Blood Press Control 2016; 9: 33-42.
Google Scholar
 
 
20.
Gebrayel P, Nicco C, Al Khodor S, et al. Microbiota medicine: towards clinical revolution. J Transl Med 2022; 20: 111.
Google Scholar
 
 
21.
Ge Y, Wang J, Wu L, Wu J. Gut microbiota: a potential new regulator of hypertension. Front Cardiovasc Med 2024; 11: 1333005.
Google Scholar
 
 
22.
Li H, Liu B, Song J, et al. Characteristics of gut microbiota in patients with hypertension and/or hyperlipidemia: a cross-sectional study on rural residents in Xinxiang County, Henan province. Microorganisms 2019; 7: 399.
Google Scholar
 
 
23.
Dan X, Mushi Z, Baili W, et al. Differential analysis of hypertension-associated intestinal microbiota. Int J Med Sci 2019; 16: 872-81.
Google Scholar
 
 
24.
Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017; 5: 14.
Google Scholar
 
 
25.
Louca P, Nogal A, Wells PM, et al. Gut microbiome diversity and composition is associated with hypertension in women. J Hypertens 2021; 39: 1810-6.
Google Scholar
 
 
26.
Palmu J, Salosensaari A, Havulinna AS, et al. Association between the gut microbiota and blood pressure in a population cohort of 6953 individuals. J Am Heart Assoc 2020; 9: e016641.
Google Scholar
 
 
27.
Sun S, Lulla A, Sioda M, et al. Gut microbiota composition and blood pressure. Hypertension 2019; 73: 998-1006.
Google Scholar
 
 
28.
Silveira-Nunes G, Durso DF, de Oliveira Jr LRA, et al. Hypertension is associated with intestinal microbiota dysbiosis and inflammation in a Brazilian population. Front Pharmacol 2020; 11: 258.
Google Scholar
 
 
29.
Takagi T, Naito Y, Kashiwagi S, et al. Changes in the gut microbiota are associated with hypertension, hyperlipidemia, and type 2 diabetes mellitus in Japanese subjects. Nutrients 2020; 12: 2996.
Google Scholar
 
 
30.
Yan Q, Gu Y, Li X, et al. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol 2017; 7: 381.
Google Scholar
 
 
31.
Kim S, Goel R, Kumar A, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci 2018; 132: 701-18.
Google Scholar
 
 
32.
Cai M, Lin L, Jiang F, et al. Gut microbiota changes in patients with hypertension: a systematic review and meta-analysis. J Clin Hypertens 2023; 25: 1053-68.
Google Scholar
 
 
33.
Toral M, Robles-Vera I, de la Visitación N, et al. Critical role of the interaction gut microbiota – sympathetic nervous system in the regulation of blood pressure. Front Physiol 2019; 10: 231.
Google Scholar
 
 
34.
Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc 2020; 4: bvz039.
Google Scholar
 
 
35.
Jaworska K, Huc T, Samborowska E, et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One 2017; 12: e0189310.
Google Scholar
 
 
36.
Santisteban MM, Qi Y, Zubcevic J, et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res 2017; 120: 312-23.
Google Scholar
 
 
37.
Yang Z, Wang Q, Liu Y, et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clin Exp Hypertens 2023; 45: 2195135.
Google Scholar
 
 
38.
Bartolomaeus H, Balogh A, Yakoub M, et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 2019; 139: 1407-21.
Google Scholar
 
 
39.
Felizardo RJF, Watanabe IKM, Dardi P, Rossoni LV, Câmara NOS. The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids. Pharmacol Res 2019; 141: 366-77.
Google Scholar
 
 
40.
Lymperopoulos A, Suster MS, Borges JI. Short-chain fatty acid receptors and cardiovascular function. Int J Mol Sci 2022; 23: 3303.
Google Scholar
 
 
41.
Onyszkiewicz M, Gawrys-Kopczynska M, Konopelski P, et al. Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon-vagus nerve signaling and GPR41/43 receptors. Pflugers Arch 2019; 471: 1441-53.
Google Scholar
 
 
42.
Roshanravan N, Mahdavi R, Alizadeh E, et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial. Horm Metab Res 2017; 49: 886-91.
Google Scholar
 
 
43.
Nakai M, Ribeiro RV, Stevens BR, et al. Essential hypertension is associated with changes in gut microbial metabolic pathways: a multisite analysis of ambulatory blood pressure. Hypertension 2021; 78: 804-15.
Google Scholar
 
 
44.
Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J 2021; 20: 301-19.
Google Scholar
 
 
45.
He S, Jiang H, Zhuo C, Jiang W. Trimethylamine/trimethylamine-n-oxide as a key between diet and cardiovascular diseases. Cardiovasc Toxicol 2021; 21: 593-604.
Google Scholar
 
 
46.
Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol 2014; 30: 1700-5.
Google Scholar
 
 
47.
Jaworska K, Bielinska K, Gawrys-Kopczynska M, Ufnal M. TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome. Cardiovasc Res 2019; 115: 1948-9.
Google Scholar
 
 
48.
Lucas SE, Walton SL, Mirabito Colafella KM, et al. Antihypertensives and antibiotics: impact on intestinal dysfunction and hypertension. Hypertension 2023; 80: 1393-402.
Google Scholar
 
 
49.
Mohammad S, Thiemermann C. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol 2021; 11: 594150.
Google Scholar
 
 
50.
Li C, Xiao P, Lin D, et al. Risk factors for intestinal barrier impairment in patients with essential hypertension. Front Med 2021; 7: 543698.
Google Scholar
 
 
51.
Wagle R, Shi F, Ayyaswamy S, Durgan DJ. Examining the role of bacterial extracellular vesicles in host blood pressure regulation. Hypertension 2023; 80 Suppl 1, doi: 10.1161/hyp.80.suppl_1.086.
CrossRef
 
Google Scholar
 
 
52.
Kitada K. Gut bacteria-derived extracellular vesicles and hypertension. Hypertens Res 2024; 47: 1994-5.
Google Scholar
 
 
53.
Kim JY, Kim CW, Oh SY, et al. Akkermansia muciniphila extracellular vesicles have a protective effect against hypertension. Hypertens Res 2024; 47: 1642-53.
Google Scholar
 
 
54.
Dinakis E, O’Donnell JA, Marques FZ. The gut-immune axis during hypertension and cardiovascular diseases. Acta Physiol 2024; 240: e14193.
Google Scholar
 
 
55.
Ferguson JF, Aden LA, Barbaro NR, et al. High dietary salt-induced dendritic cell activation underlies microbial dysbiosis-associated hypertension. JCI Insight 2019; 5: e126241.
Google Scholar
 
 
56.
Yan X, Jin J, Su X, et al. intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension. Circ Res 2020; 126: 839-53.
Google Scholar
 
 
57.
Jama HA, Marques FZ. Don’t take it with a pinch of salt: how sodium increases blood pressure via the gut microbiota. Circ Res 2020; 126: 854-6.
Google Scholar
 
 
58.
Fagunwa O, Davies K, Bradbury J. The human gut and dietary salt: the Bacteroides/Prevotella ratio as a potential marker of sodium intake and beyond. Nutrients 2024; 16: 942.
Google Scholar
 
 
59.
Wang X, Lang F, Liu D. High-salt diet and intestinal microbiota: influence on cardiovascular disease and inflammatory bowel disease. Biology 2024; 13: 674.
Google Scholar
 
 
60.
Mishima E, Abe T. Role of the microbiota in hypertension and antihypertensive drug metabolism. Hypertens Res 2022; 45: 246-53.
Google Scholar
 
 
61.
Wang L, Hu J. Unraveling the gut microbiota’s role in salt-sensitive hypertension: current evidences and future directions. Front Cardiovasc Med 2024; 11: 1410623.
Google Scholar
 
 
62.
Elijovich F, Laffer CL, Sahinoz M, Pitzer A, Ferguson JF, Kirabo A. The gut microbiome, inflammation, and salt-sensitive hypertension. Curr Hypertens Rep 2020; 22: 79.
Google Scholar
 
 
63.
Galla S, Chakraborty S, Cheng X, et al. Disparate effects of antibiotics on hypertension. Physiol Genomics 2018; 50: 837-45.
Google Scholar
 
 
64.
Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension – a case report. Int J Cardiol 2015; 201: 157-8.
Google Scholar
 
 
65.
Pepine CJ, Thiel A, Kim S, et al. Potential of minocycline for treatment of resistant hypertension. Am J Cardiol 2021; 156: 147-9.
Google Scholar
 
 
66.
Lin L, Xu S, Cai M, et al. Effects of fecal microbiota transfer on blood pressure in animal models: a systematic review and meta-analysis. PLoS One 2024; 19: e0300869.
Google Scholar
 
 
67.
Zhong HJ, Zeng HL, Cai YL, et al. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol 2021; 11: 679624.
Google Scholar
 
 
68.
Zecheng L, Donghai L, Runchuan G, et al. Fecal microbiota transplantation in obesity metabolism: a meta-analysis and systematic review. Diabetes Res Clin Pract 2023; 202: 110803.
Google Scholar
 
 
69.
Olveira G, González-Molero I. An update on probiotics, prebiotics and symbiotics in clinical nutrition. Endocrinol Nutr 2016; 63: 482-94.
Google Scholar
 
 
70.
Maftei NM, Raileanu CR, Balta AA, et al. The potential impact of probiotics on human health: an update on their health-promoting properties. Microorganisms 2024; 12: 234.
Google Scholar
 
 
71.
Niness KR. Inulin and oligofructose: what are they? J Nutr 1999; 129 (7 Suppl): 1402-6S.
Google Scholar
 
 
72.
Delzenne NM, Cani PD, Daubioul C, Neyrinck AM. Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 2005; 93 Suppl 1: 157-61.
Google Scholar
 
 
73.
Mahboobi S, Rahimi F, Jafarnejad S. Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Adv Pharm Bull 2018; 8: 565-74.
Google Scholar
 
 
74.
Dehghan P, Farhangi MA, Tavakoli F, Aliasgarzadeh A, Akbari AM. Impact of prebiotic supplementation on T-cell subsets and their related cytokines, anthropometric features and blood pressure in patients with type 2 diabetes mellitus: a randomized placebo-controlled Trial. Complement Ther Med 2016; 24: 96-102.
Google Scholar
 
 
75.
Faghihimani Z, Namazi N, Ghaffari S, et al. Effects of inulin type-carbohydrates on blood pressure: a systematic review and meta-analysis. Int J Food Prop 2021; 24: 129-39.
Google Scholar
 
 
76.
Qi D, Nie XL, Zhang JJ. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis. Lipids Health Dis 2020; 19: 79.
Google Scholar
 
 
77.
Zhao TX, Zhang L, Zhou N, Sun DS, Xie JH, Xu SK. Long-term use of probiotics for the management of office and ambulatory blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Food Sci Nutr 2022; 11: 101-13.
Google Scholar
 
 
78.
Zarezadeh M, Musazadeh V, Ghalichi F, et al. Effects of probiotics supplementation on blood pressure: an umbrella meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2023; 33: 275-86.
Google Scholar
 
 
79.
Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014; 64: 897-903.
Google Scholar
 
 
80.
Teo YQJ, Chong B, Soong RY, Yong CL, Chew NW, Chew HSJ. Effects of probiotics, prebiotics and synbiotics on anthropometric, cardiometabolic and inflammatory markers: an umbrella review of meta-analyses. Clin Nutr 2024; 43: 1563-83.
Google Scholar
 
 
81.
van Hemert S, Ormel G. Influence of the multispecies probiotic Ecologic® BARRIER on parameters of intestinal barrier function. Food Nutr Sci 2014; 5: 1739-45.
Google Scholar
 
 
82.
Gomez Quintero DF, Kok CR, Hutkins R. The future of synbiotics: rational formulation and design. Front Microbiol 2022; 13: 919725.
Google Scholar
 
 
83.
Hadi A, Pourmasoumi M, Kazemi M, Najafgholizadeh A, Marx W. Efficacy of synbiotic interventions on blood pressure: a systematic review and meta-analysis of clinical trials. Crit Rev Food Sci Nutr 2022; 62: 5582-91.
Google Scholar
 
 
84.
Arabi SM, Bahrami LS, Rahnama I, Sahebkar A. Impact of synbiotic supplementation on cardiometabolic and anthropometric indices in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2022; 176: 106061.
Google Scholar
 
 
85.
Naseri K, Saadati S, Yari Z, et al. Beneficial effects of probiotic and synbiotic supplementation on some cardiovascular risk factors among individuals with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials. Pharmacol Res 2022; 182: 106288.
Google Scholar
 
 
Share
Send by email
RELATED ARTICLE
Gut microbiota and insomnia: Mendelian randomization and network pharmacology to predict potential intervention with traditional Chinese medicine
Exploring the association between gut microbiota and venous thromboembolism using a Mendelian randomization analysis
Exploring the mediating role of the plasma lipidome in the pathway from the gut microbiota to dementia: a Mendelian randomization study
Identifying the causal relationship between gut microbiota and lymphoma disease: a Mendelian randomization study and meta-analysis
Diagnostic accuracy of non-invasive investigations for coronary artery disease in hypertensive patients: a meta-analysis
Indexes
 
Keywords index
Topics index
Authors index
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
© 2006-2025 Journal hosting platform by Bentus
Scroll to top